Ireland
--:--IST
Latest
Clinical Trials in Denmark / NCT07427251
Recruiting Phase 4

The Postprandial Hypo-Avoid Study

NCT07427251 · tracked via the Priya Life Science Denmark tracker
Phase
Phase 4
Started
2026-04-27
Last updated
2026-08-13

Condition(s) studied

Type 1 Diabetes Mellitus

Investigational drug(s) / intervention(s)

Low-Dose Glucagon →Glucose Arm

Low-Dose Glucagon: Participants will be given a low-dose of glucagon before starting the exercise session

Glucose Arm: Participants will be given a dose of glucose before starting exercise

Study summary

The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system.

The primary endpoint is the difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Type 1 diabetes ≥ 2 years * Using an automated insulin delivery system for ≥ 3 months * NovoRapid or Fiasp use ≥1 week * Proficiency in carbohydrate counting Exclusion Criteria: * Allergies to lactose or glucagon * Known or suspected allergies to glucagon or related products * History of hypersensitivity or allergic reaction to glucagon or lactose * Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis * Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation * Lack of compliance with key study procedures at the discretion of the investigator * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (\>12 months since last period) are not required to use contraception) * Inability to understand the individual information and to give informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Steno Diabetes Center Copenhagen Herlev Denmark Recruiting

More Steno Diabetes Center Copenhagen trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07427251 on ClinicalTrials.gov ↗ ← All trials in Denmark